Perrigo’s Generic Loratadine Offerings Could Boost Firm’s Cough/Cold Sales
This article was originally published in The Tan Sheet
Executive Summary
Perrigo's planned introduction of two generic loratadine formulations in early 2004 is expected to improve the firm's lackluster cough/cold sales in the second half of its fiscal year
You may also be interested in...
Leiner Looks To Rule Claritin Equivalent Market With Summer Launches
Leiner Health Products will seek to control the store brand loratadine market with late summer launches of equivalents to Schering-Plough's Claritin RediTabs and D-24
Loratadine Sales Keep Perrigo On Track To Meet Core Business Growth Goals
Perrigo expects to meet its fiscal 2004 target for core business growth despite continued delays in the approval of its 10 mg loratadine tablets (Schering-Plough's Claritin)
Perrigo Expands UK Presence With Vitamin Manufacturer Acquisition
Perrigo's $13 mil. purchase of Peter Black Pharmaceuticals provides the private labeler with a foothold to develop a UK vitamin market presence